Download PDFPDF

Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Cannabinoids, multiple sclerosis and aluminium?

    Dear Editor,

    I have read with interest the eLetter concerning the recent paper on the use of cannabinoids as therapy in MS.

    If the suggestion is correct that patients receiving cannabinoid therapy suffered a higher number of relapses then it might be pertinent to point out that cannabinoid extracts, such as THC, as well as cannabis resin, include a very high content of aluminium (as much as 0.4 mg Al/g T...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Are MS-relapses and infections more frequent in patients who receive cannaboids for 12 months?

    Dear Editor,

    This is a very interesting, thorough and highly relevant study, and I want to congratulate the authors for it.

    There is one question, however, that I would like to ask for clarificat...

    Show More
    Conflict of Interest:
    None declared.